好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Obstructive Sleep Apnea Predicts Increased Brain Atrophy in Patients with Multiple Sclerosis Independent of Obesity
Multiple Sclerosis
P3 - Poster Session 3 (5:30 PM-6:30 PM)
6-014
To determine if obstructive sleep apnea (OSA) predicts multiple sclerosis (MS) disease burden independent of obesity, a known risk factor for both OSA and for MS-associated brain atrophy. 
Recent studies found that patients with MS and OSA had higher body mass index (BMI), more brainstem lesions, and more brain atrophy than patients with MS without OSA. It is currently unknown whether OSA can develop due to MS disease activity alone or if it stems from other established factors like obesity.
We collected whole brain volumes (WBV), gray matter volumes (GMV), and WBV and GMV age-normalized percentiles from the MRIs of patients with both MS and OSA. To control for obesity, we categorized patients into two groups: MS and OSA with obesity (BMI ≥ 30) and MS and OSA without obesity (BMI < 30). We utilized multivariable linear regression to assess differences in brain atrophy in these two groups. 
We identified 39 patients for inclusion in this study: 26 patients with OSA and obesity and 13 patients with OSA without obesity. By multivariable linear regression, we found that non-obese OSA patients had lower WBV (P = 0.027), GMV (P = 0.039), WBV% (P = 0.029), and GMV% (P = 0.048) than obese OSA patients, controlling for MS disease duration, blood pressure, tobacco use, and older age, all risk factors for brain atrophy. 
OSA is associated with greater brain atrophy independent of obesity in patients with MS. 
Authors/Disclosures
Alexandra R. Balshi
PRESENTER 		Ms. Balshi has nothing to disclose.
John Dempsey, BA (SUNY Upstate Medical University) Mr. Dempsey has nothing to disclose.
Jacob A. Sloane, MD, PhD (Beth Israel Deaconess Medical Center) Dr. Sloane has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for biogen. Dr. Sloane has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Sloane has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi.